Method of treating thrombocytopenia
View Patent ↗Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
1. A combination of agents comprising: 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof and an anti-clotting agent.
2. A combination according to claim 1 , wherein the anti-clotting agent is selected from: heparin, warfarin, enoxaparin, aspirin, clopidogrel, ticlopidine, dipyridamole, prasugrel, tissue plasminogen activator, hirudin, lepirudin, argatroban, Ximelagatran, bivalirudin, dabigatran etexilate, rivaroxaban, apixaban, YM150, DU-176b, LY517717, PRT054021, rivaroxaban, fondaparinux, Idraparinux, tick anticoagulant peptide, antistatin, DX 9065a, Org31540/SR90107A, active-site blocked Factor IXa, monoclonal anti-Factor IXa, protein C derivative, recombinant thrombomodulin, tissue factor inhibitor, mutant tissue factor, factor Vila inhibitor (Factor Vllai), and Factor Vila/tissue factor blocker (TFPI, NAPc2).
3. A combination according to claim 2 wherein the compounds are administered orally.
4. A combination according to claim 2 wherein one compound is administered orally and one compound is administered parenterally.